Aaron Mendelsohn - Second Sight Director
| EYESDelisted Stock | USD 4.14 0.20 4.61% |
Director
Mr. Aaron Mendelsohn is Independent Director of the CompanyMr. Mendelsohn is a founder and has served as a director of Second Sight since inception. Mr. Mendelsohn served on the board of Advanced Bionics since shortly after its founding in 1993 until its sale in 2004. Mr. Mendelsohn was also a founder and director of Medical Research Group from its inception in 1998 until its sale in 2001 to Medtronic, Inc. Mr. Mendelsohn previously served on the board of directors for the Alfred E. Mann Institute for Biomedical Engineering at the University of Southern California since its inception in 1998 until mid2016. Mr. Mendelsohn is a founder and, since 2007, a director of Nanoprecision Holding Company, Inc., a company engaged in manipulating materials at nanometer scale. He is also a founder and director of Nanoprecision Medical, Inc., a drug delivery company working in nanotechnology, since its inception in 2011. Mr. Mendelsohn is a founder and serves as Chairman of the Maestro Foundation since it was organized in 1983. The Maestro Foundation is a leading nonprofit musical philanthropic organization which hosts a premier chamber music series and lends professionallevel instruments and bows to young, careerbound classical musicians
| Age | 66 |
| Phone | 818 833-5000 |
| Web | www.secondsight.com |
Second Sight Management Efficiency
The company has return on total asset (ROA) of (10.74) % which means that it has lost $10.74 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (19.02) %, meaning that it created substantial loss on money invested by shareholders. Second Sight's management efficiency ratios could be used to measure how well Second Sight manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 199 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Second Sight Medical has a current ratio of 24.75, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Second Sight until it has trouble settling it off, either with new capital or with free cash flow. So, Second Sight's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Second Sight Medical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Second to invest in growth at high rates of return. When we think about Second Sight's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| David Raisbeck | Eastman Chemical | 71 | |
| Michael Connors | Eastman Chemical | 62 | |
| Charles Stevens | Eastman Chemical | 61 | |
| Vanessa Sutherland | Eastman Chemical | 48 | |
| Richard Blakey | Employers Holdings | 70 | |
| Harriet Edelman | Assurant | 65 | |
| Larry Webb | Cincinnati Financial | 62 | |
| Charles Koch | Assurant | 72 | |
| Valerie Glenn | Employers Holdings | 65 | |
| Renee Hornbaker | Eastman Chemical | 68 | |
| Norman Edelcup | Valhi Inc | 78 | |
| Humberto Alfonso | Eastman Chemical | 63 | |
| Gregory Ziegler | Cincinnati Financial | N/A | |
| Gretchen Price | Cincinnati Financial | 63 | |
| Hank Brown | Sensient Technologies | 78 | |
| Elaine Wedral | Sensient Technologies | 77 | |
| Edward Cichurski | Sensient Technologies | 79 | |
| Fergus Clydesdale | Sensient Technologies | 79 | |
| Hayden McIlroy | Valhi Inc | 78 | |
| Elyse Douglas | Assurant | 61 | |
| Deborah McKeithanGebhardt | Sensient Technologies | 62 | |
Management Performance
| Return On Equity | -19.02 | |||
| Return On Asset | -10.74 |
Second Sight Medical Leadership Team
Elected by the shareholders, the Second Sight's board of directors comprises two types of representatives: Second Sight inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Second. The board's role is to monitor Second Sight's management team and ensure that shareholders' interests are well served. Second Sight's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Second Sight's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Blake, CFO | ||
| Patrick Ryan, COO | ||
| Frank Vandeputte, Vice President General Manager | ||
| Anthony Moses, Commercial Vice President - Americas | ||
| Edward Randolph, VP of Manufacturing | ||
| Gregg Williams, Independent Director | ||
| Alfred Mann, Co-Founder, Chairman Emeritus, Member of Audit Committee, Member of Nominating and Governance Committee and Member of Compensation Committee | ||
| Jonathan McGuire, President CEO, Director | ||
| Stephen Okland, Commercial Vice President U.S. and Canada | ||
| Gregoire Cosendai, VP of European Operations | ||
| Steven Okland, Commercial Vice President U.S. and Canada | ||
| William Link, Independent Director | ||
| Thomas Miller, CFO | ||
| James Miller, Director - Manufacturing | ||
| Will McGuire, President CEO, Director | ||
| David Jacques, Vice President - Research & Development | ||
| Aaron Mendelsohn, Director | ||
| Robert Greenberg, President CEO, Director | ||
| Matthew Pfeffer, Independent Director |
Second Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Second Sight a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -19.02 | |||
| Return On Asset | -10.74 | |||
| Current Valuation | 11.54 M | |||
| Shares Outstanding | 39.41 M | |||
| Shares Owned By Insiders | 28.61 % | |||
| Shares Owned By Institutions | 7.01 % | |||
| Number Of Shares Shorted | 1.19 M | |||
| Price To Earning | (1.61) X | |||
| Price To Book | 0.93 X | |||
| Price To Sales | 616.54 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Second Sight in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Second Sight's short interest history, or implied volatility extrapolated from Second Sight options trading.
Pair Trading with Second Sight
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Second Sight position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Second Sight will appreciate offsetting losses from the drop in the long position's value.Moving against Second Stock
| 0.66 | BSX | Boston Scientific Corp Financial Report 24th of April 2024 | PairCorr |
| 0.64 | ALGN | Align Technology Financial Report 24th of April 2024 | PairCorr |
| 0.63 | EW | Edwards Lifesciences Corp Financial Report 24th of April 2024 | PairCorr |
| 0.58 | DXCM | DexCom Inc Financial Report 25th of April 2024 | PairCorr |
| 0.51 | ZBH | Zimmer Biomet Holdings Financial Report 7th of May 2024 | PairCorr |
The ability to find closely correlated positions to Second Sight could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Second Sight when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Second Sight - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Second Sight Medical to buy it.
The correlation of Second Sight is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Second Sight moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Second Sight Medical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Second Sight can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. Note that the Second Sight Medical information on this page should be used as a complementary analysis to other Second Sight's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Consideration for investing in Second Stock
If you are still planning to invest in Second Sight Medical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Second Sight's history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |